No Prescription |
 |
 | ||
|
Topamac |
|
| ||
No Prescription » Prescription Drugs 16 » Topamac Topiramate is used for: Treating certain kinds of seizures in patients 2 years of age or older. It is also prescribed to prevent migraine headache in adults. Topiramate is a seizure medication also called an anticonvulsant.Topiramate is used alone or in combination with other medications to prevent seizures in adults and children who are at least 2 years old. Topiramate is also used to prevent migraine headaches. Topiramate will only prevent migraine headaches or reduce the number of attacks. It will not treat a headache that has already begun. Buy Topamac and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About Topamac: Product Type: Prescription Drugs 16 Topamac/Topamax ( Generic Topiramate ) Topamac/Topamax (Generic Topiramate) Generic Topiramate 100mg Generic Topiramate Topamac/Topamax
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
